Amoxicillin Equals Amoxicillin-Clavulanate for Acute Sinusitis

The First-Line Dilemma in Acute Sinusitis

Acute rhinosinusitis is one of the most common diagnoses driving outpatient antibiotic prescriptions, yet the optimal first-line therapy remains a subject of ongoing debate. Historically, clinical practice guidelines have shifted recommendations between standard amoxicillin and broader-spectrum amoxicillin-clavulanate, leading to highly variable prescribing patterns in primary care [1, 2]. While broader coverage theoretically targets resistant pathogens, it also carries well-documented risks of gastrointestinal distress and opportunistic fungal infections [3]. Balancing the need for effective symptom resolution against the imperative of antibiotic stewardship requires high-quality comparative data [4, 5]. A large retrospective cohort study now clarifies whether the addition of clavulanate actually improves clinical outcomes for uncomplicated cases in adults, providing actionable data for daily prescribing decisions.

Nationwide Cohort and Propensity Matching

Acute sinusitis drives the highest rate of antibiotic prescribing in adults younger than 65 years, yet consensus is lacking on the best initial therapy. To resolve this clinical uncertainty, researchers designed a retrospective cohort study using a nationwide health care utilization database to compare standard-dose amoxicillin-clavulanate against standard-dose amoxicillin. The investigators evaluated adults aged 18 to 64 years diagnosed with outpatient acute sinusitis between January 1, 2018, and December 1, 2023. The full cohort initially included 521,244 eligible patients. Because observational data can be skewed by prescribing biases (where sicker patients might systematically receive broader-spectrum drugs), the researchers utilized propensity score matching. This statistical technique balances baseline patient characteristics and comorbidities between treatment arms to simulate a randomized trial. After matching, the final analysis included 234,608 patients, evenly divided with 117,304 patients per group. This balanced cohort was 65.5% female with a median age of 43 years (interquartile range [IQR], 31-54 years). The analysis specifically compared two common outpatient regimens. The standard-dose amoxicillin-clavulanate exposure was 875 mg-125 mg twice daily, while the standard-dose amoxicillin exposure was either 875 mg twice daily or 500 mg three times daily.

Treatment Failure Rates Show No Added Benefit

To evaluate clinical efficacy, the researchers tracked treatment failure between 1 and 14 days after antibiotic initiation. They defined failure as the need for a new antibiotic prescription, an emergency department visit, or an inpatient admission for either acute sinusitis or a related complication. Across the entire matched cohort, treatment failure occurred in just 3.1% of patients overall. Severe cases requiring escalated care were exceptionally rare, with only 0.03% of patients requiring an emergency department or inpatient encounter. When comparing the two regimens, the investigators found no observed difference in the risk of treatment failure between the amoxicillin-clavulanate and amoxicillin groups (3.0% versus 3.1%; risk ratio [RR], 0.96 [95% CI, 0.92-1.01]). This lack of difference remained consistent across multiple sensitivity analyses. For practicing clinicians, these data strongly suggest that escalating to a beta-lactamase inhibitor for routine, uncomplicated sinusitis does not improve the likelihood of symptom resolution or prevent disease progression.

The Cost of Broader Coverage: Secondary Infections

While broader antimicrobial coverage failed to improve efficacy, it did carry distinct downstream consequences for patient safety. General antibiotic-associated adverse events were similar between the two groups (1.3% for amoxicillin-clavulanate versus 1.2% for amoxicillin; RR, 1.04 [95% CI, 0.97-1.12]). However, the risk of secondary infections was significantly higher for patients receiving the combination therapy. This elevated risk is driven by the disruption of normal gastrointestinal and genitourinary flora, which allows opportunistic pathogens to proliferate. Notably, yeast infections were more frequent with amoxicillin-clavulanate compared to amoxicillin (1.1% versus 0.8%; RR, 1.40 [95% CI, 1.29-1.53]). More concerning for clinicians, Clostridioides difficile infections were more than twice as likely in the amoxicillin-clavulanate group (0.04% versus 0.02%; RR, 2.14 [95% CI, 1.29-3.54]). Although the absolute incidence of these complications remains low, the relative harm is clear. Because the addition of clavulanate offers no measurable benefit in preventing treatment failure but significantly increases the risk of opportunistic infections, these findings support standard-dose amoxicillin as the preferred first-line treatment for adults presenting with uncomplicated acute sinusitis.

References

1. Dhar S, Kothari DS, Tomescu AL, et al. Antimicrobial Prescription Patterns for Acute Sinusitis 2015-2022: A Comparison to Published Guidelines.. American journal of rhinology & allergy. 2024. doi:10.1177/19458924241280379

2. Arnold M, Nicholas B. Impact of clinical practice guidelines: trends in antibiotic prescriptions for acute rhinosinusitis. International Forum of Allergy and Rhinology. 2020. doi:10.1002/alr.22750

3. Gillies M, Ranakusuma A, Hoffmann T, et al. Common harms from amoxicillin: a systematic review and meta-analysis of randomized placebo-controlled trials for any indication. Canadian Medical Association Journal. 2014. doi:10.1503/cmaj.140848

4. Kasse G, Cosh SM, Humphries J, Islam MS. Antimicrobial prescription pattern and appropriateness for respiratory tract infection in outpatients: a systematic review and meta-analysis. Systematic Reviews. 2024. doi:10.1186/s13643-024-02649-3

5. Bell B, Schellevis F, Stobberingh EE, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antibiotic consumption on antibiotic resistance. BMC Infectious Diseases. 2014. doi:10.1186/1471-2334-14-13